Prescription medicine
Naratriptan First approved as Amerge
Naratriptan (Amerge) is a prescription medicine with an FDA approval on record since 1998. FDA's NDC Directory lists it from 4 generic labelers, and pharmacies paid $1.08 per naratriptan HCl 2.5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the naratriptan FDA label on DailyMed (effective October 30, 2025, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.); the NDA 20763 record on Drugs@FDA; every naratriptan label on DailyMed.
Highlights of the record
FDA label of October 30, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageNaratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths
- 1 mg
- 2.5 mg
Tablet; film-coated tablet.
On the market
- Earliest approval on file
- February 10, 1998 Amerge, Glaxosmithkline Llc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 9 first July 7, 2010; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 4 of which 4 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1.08 per tablet Naratriptan HCl 2.5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 1,369 through July 30, 2026
What is naratriptan used for?
From the label: indications and usageNaratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. Naratriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of naratriptan tablets have not been established for cluster headache. […]
Conditions named in the indications of naratriptan's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist.
Source: FDA drug label (naratriptan), Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective October 30, 2025 (SPL set 41c29652-32f8-48dc-9038-0e2195aa2084), via openFDA; the full label on DailyMed
What does the patient leaflet for naratriptan say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about naratriptan tablets?Naratriptan tablets can cause serious side effects, including: Heart attack and other heart problems. Heart problems may lead to death. Stop taking naratriptan tablets and get emergency medical help right away if you have any of the following symptoms of a heart attack: • discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw • pain or discomfort in your arms, back, neck, jaw, or stomach • shortness of breath with or without chest discomfort • breaking out in a cold sweat • nausea or vomiting • feeling lightheaded Naratriptan tablets are not for people with risk factors for heart disease unless a heart exam is done and shows no problem. You have a higher risk for heart disease if you: • have high blood pressure • have high cholesterol levels • smoke • are overweight • have diabetes • have a family history of heart disease
From the patient leaflet: What should I avoid while taking naratriptan tablets?Naratriptan tablets can cause dizziness, weakness, or drowsiness. If you have these symptoms, do not drive a car, use machinery, or do anything where you need to be alert.
From the patient leaflet: How should I store naratriptan tablets?Store naratriptan tablets between 20°C and 25°C (68°F and 77°F). [See USP Controlled Room Temperature] Keep naratriptan tablets and all medicines out of the reach of children.
Source: FDA drug label (naratriptan), Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective October 30, 2025 (SPL set 41c29652-32f8-48dc-9038-0e2195aa2084), via openFDA; the full label on DailyMed
Is there a generic for naratriptan (Amerge)?
The FDA approved the first generic naratriptan on July 7, 2010. 9 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists naratriptan from 4 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1998 earliest approval on file
- 2010 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for naratriptan (Amerge)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.08 per Naratriptan HCl 2.5 mg tablet, down 8% from $1.17 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Naratriptan HCl 2.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Naratriptan HCl 1 mg tablet | Generic | $1.78 per tablet | $53.29 | +3% |
| Naratriptan HCl 2.5 mg tablet | Generic | $1.08 per tablet | $32.51 | -8% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the naratriptan label say about other medicines?
The naratriptan label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Dihydroergotamine | contraindications | … within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 , 7.2 )] Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9) ] Severe renal or hepatic … |
| Ergotamine | warnings and precautions | Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). |
Source: FDA drug label (naratriptan), Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., effective October 30, 2025 (SPL set 41c29652-32f8-48dc-9038-0e2195aa2084), via openFDA; the full label on DailyMed
What do FAERS reports show for naratriptan?
The FDA Adverse Event Reporting System holds 1,369 reports that list naratriptan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 20 are coded as a death and 278 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as naratriptan?
12 other medicines are given the same way (oral) and in the same FDA class as naratriptan or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Eletriptan | Migraine | 10 labelers | $1.75 per tablet 40 mg tablet | No current entry |
| Almotriptan | Migraine | 3 labelers | $16.86 per tablet 12.5 mg tablet | No current entry |
| Naproxen and sumatriptan | Migraine | 3 labelers | $10.46 per unit 85-500 mg | No current entry |
| Frovatriptan | Migraine | 4 labelers | $2.72 per tablet 2.5 mg tablet | A presentation being discontinued |
| Meloxicam and rizatriptan | Migraine | none listed | $122.64 per tablet 20-10 mg tablet | No current entry |
Every medicine labeled for the same conditions as naratriptan
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to naratriptan
- 12 medicines for the same use
- Other triptans
- the pharmacologic class, with prices and generics
- Naratriptan side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other